PIAS3

Across TCGA pan-cancer cohorts, PIAS3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PIAS3 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PIAS3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PIAS3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where PIAS3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.290	0.736	.002	40	view →
LUAD	DFS	Tertile	II,III,IV	0.588	0.356	.033	4	view →
LSCC	OS	Median	III,IV	0.893	0.581	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PIAS3–PDAC (DFS)

Open the PDAC breakdown →